March 5, 2021

Sarilumab in Patients Admitted to Hospital with Severe or Critical COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• In a randomized, placebo-controlled, double-blind trial, the IL-6 receptor inhibitor sarilumab did not reduce the median time to improvement by day 29 among patients hospitalized for COVID-19 compared to placebo (n=416). Patients receiving placebo had a median time to improvement of 12 days, compared to 10 days among those receiving either 200 mg or 400 mg of sarilumab (HR=1.03 and HR=1.14, respectively). No significant differences were observed in proportions of patients alive by day 29 across the three groups.

Lescure et al. (Mar 4, 2021). Sarilumab in Patients Admitted to Hospital with Severe or Critical COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Respiratory Medicine. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00099-0/fulltext